Skip to content

Pessary (cervical Ring) plus Progesterone to prevent Preterm delivery

Pessary plus Progesterone to prevent Preterm delivery in women with short cervical length: randomized clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3t8prz
Enrollment
Unknown
Registered
2016-09-08
Start date
2015-06-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm delivery, Maternal care for cervical incompetence, Maternal care for other abnormalities of cervix, Uterine Cervical Incompetence

Interventions

Control group: Progesterone 234 pregnant women with cervical measure below 30 mm and 234 pregnant women with cervical measure below 25 mm receive micronized progesterone, 200 mg per day to be administ
Drug
Device
E04.520.100
D05.750.900.850.900

Sponsors

UNIVERSIDADE ESTADUAL DE CAMPINAS
Lead Sponsor
UNIVERSIDADE ESTADUAL DE CAMPINAS
Collaborator
Faculdade de Medicina de Jundiaí
Collaborator
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
Collaborator
Hospital das Clínicas da Universidade Federal do Rio Grande do Sul
Collaborator
Hospital Dom Malan
Collaborator
Hospital Maternidade Vila Nova Cachoeirinha
Collaborator
Hospital Universitário Lauro Wanderley daUniversidade Federal da Paraíba
Collaborator
Instituto de Medicina Integral Prof. Fernandes Figueira IMIP
Collaborator
Instituto Fernandes Figueira
Collaborator

Eligibility

Sex/Gender
Female
Age
10 Years to No maximum

Inclusion criteria

Inclusion criteria: pregnant women between 18 weeks and 0 days and 22 weeks and 6 days of gestation with cervical length lower or equal 30 mm

Exclusion criteria

Exclusion criteria: Placenta previa diagnosed by US second or third quarter; greater than 1 cm cervical dilatation; painful uterine activity; active vaginal bleeding; cervical cerclage in the current pregnancy; cervical length <5 mm; Rupture of Membranes; severe liver disease; cholestasis occurred while current pregnancy; History or thromboembolic event during the pregnancy; monoamniotic Twin pregnancy; Multiple pregnancies with 3 or more fetuses; ultrasonographic signs of fetal-fetal transfusion; selective growth restriction diagnosis of type 2 or 3 Gratacós; Major fetal anomalies; Fetal death

Design outcomes

Primary

MeasureTime frame
Neonatal morbimortality of pregnant women using cervical pessary plus progesterone versus progesterone only.

Secondary

MeasureTime frame
Gestational age at birth; mode of delivery; weight adequacy for gestational age; newborn vitality; sex of the newborn; preterm birth before 28, 32, 34 and 37 weeks of gestational age; days of neonatal intensive care unit admission; days of maternal admissions during pregnancy; screening, neonatal and maternal admissions costs; pessary use symptoms; spontaneous preterm birth and preterm rupture of membranes rates; imemdiate neonatal outcomes

Countries

Brazil

Contacts

Public ContactRodolfo Pacagnella

UNIVERSIDADE ESTADUAL DE CAMPINAS

rodolfo@caism.unicamp.br+55 (19) 3521 9336

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Mar 1, 2026